Actively Recruiting
Cognitive Assessment Tools for Individuals With Huntington's Disease
Led by Ohio State University · Updated on 2026-03-02
76
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are exploring two cognitive tools, the Coding Test and the Self-Administered Gerocognitive Examination (SAGE), which are not commonly used in Huntington Disease (HD) clinical trials. These tools have been applied in other neurodegenerative diseases like Alzheimer's, Parkinson's, and Lewy Body Disease, but their usefulness in HD patients is not well understood. The study aims to expand knowledge about these tools for initial screening and clinical trial use in HD. Participants will attend a single visit lasting about 1 to 1.5 hours at the OSU Wexner Medical Center Huntington Society of America Center of Excellence Clinic. During this visit, vital signs such as weight, blood pressure, temperature, respiratory rate, and pulse will be measured. Medical records will be reviewed for demographics, medications, medical and surgical history, family history of HD, and diagnosis details. Participants will complete cognitive, functional, and motor assessments using a standardized battery. Throughout the visit, researchers will document any adverse events and perform assessments including the Symbol Digit Modality Test (SDMT), Coding Test, Self-Administered Gerocognitive Examination (SAGE), Luria test, and parts of the Unified Huntington's Disease Rating Scale (UHDRS). They will analyze correlations between various test scores and HD symptom onset age. The study focuses on evaluating cognitive tools in HD patients aged 30 to 65 who meet specific genetic and clinical diagnosis criteria.
CONDITIONS
Brief Title
Cognitive Assessment Tools for Huntington's Disease.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males and females aged 30-65 (inclusive) at the time of signing the informed consent form
- Genetic diagnosis of Huntington Disease with a CAG repeat size of 40 or greater
- Clinical diagnosis of Huntington Disease with a Diagnostic Confidence Level (DCL) of 4
- Vision and hearing sufficient to complete study tests
- Stable dose of medications for at least 30 days before signing the informed consent form
You will not qualify if you...
- Age of symptom onset less than 19 years or greater than 60 years
- Serious neurological disorders other than Huntington Disease, such as Alzheimer's, Parkinson's, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, or Traumatic Brain Injury
- Ongoing serious medical conditions considered significant by the investigator, including autoimmune diseases, cancer treatment, congestive heart failure, severe pulmonary disease, or seizure disorder
- Pregnancy or breastfeeding
- History of a learning disability
- Inability to provide consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment
Duration - 1 to 1.5 hours
Participants complete a one-time visit to undergo cognitive, functional, and motor assessments, along with vital signs measurement and medical record review.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States, 43221
Actively Recruiting
Research Team
N
Nicole E Vrettos
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here